Auranofin Inhibits the Enzyme Activity of Pasteurella multocida Toxin PMT in Human Cells and Protects Cells from Intoxication

Stefan Carle 1, Thorsten Brink 2, Joachim H. C. Orth 2, Klaus Aktories 2,3 and Holger Barth 1,*

1 Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Albert-Einstein-Allee 11, Ulm 89081, Germany; stefan.carle@uni-ulm.de
2 Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Freiburg 79104, Germany; thorsten.brink@pharmakol.uni-freiburg.de (T.B.); joachim.orth@pharmakol.uni-freiburg.de (J.H.C.O.); klaus.aktories@pharmakol.uni-freiburg.de (K.A.)
3 Centre for Biological Signalling Studies (BIOSS), University of Freiburg, Freiburg 79104, Germany
* Correspondence: holger.barth@uni-ulm.de; Tel.: +49-731-500-65503; Fax: +49-731-500-65502

Academic Editor: Katharina Kubatzky
Received: 16 November 2016; Accepted: 10 January 2017; Published: 13 January 2017

Abstract: The AB-type protein toxin from Pasteurella multocida (PMT) contains a functionally important disulfide bond within its catalytic domain, which must be cleaved in the host cell cytosol to render the catalytic domain of PMT into its active conformation. Here, we found that the reductive potential of the cytosol of target cells, and more specifically, the activity of the thioredoxin reductase (TrxR) is crucial for this process. This was demonstrated by the strong inhibitory effect of the pharmacological TrxR inhibitor auranofin, which inhibited the intoxication of target cells with PMT, as determined by analyzing the PMT-catalyzed deamidation of GTP-binding proteins (G-proteins) in the cytosol of cells. The amount of endogenous substrate levels modified by PMT in cells pretreated with auranofin was reduced compared to cells treated with PMT alone. Auranofin had no inhibitory effect on the activity of the catalytic domain of constitutively active PMT in vitro, demonstrating that auranofin did not directly inhibit PMT activity, but interferes with the mode of action of PMT in cells. In conclusion, the results show that TrxR is crucial for the mode of action of PMT in mammalian cells, and that the drug auranofin can serve as an efficient inhibitor, which might be a starting point for novel therapeutic options against toxin-associated diseases.

Keywords: Pasteurella multocida toxin (PMT); deamidation; G-protein; thioredoxin reductase (TrxR); auranofin

1. Introduction

Pasteurella multocida toxin (PMT) is one of several virulence factors that can be expressed by the gram-negative bacterium P. multocida, which is a pathogen for various livestock [1–3]. This toxin belongs to the group of AB-type protein toxins, meaning that it is composed of an enzymatically-active A-domain and a receptor-binding/translocation B-domain. It is the causative agent for atrophic rhinitis in pigs, which leads to the destruction of the turbinates within the nasal cavity and the characteristic deformation of the snout [4]. On the molecular level, PMT specifically deamidates certain heterotrimeric G-proteins. Heterotrimeric G-proteins are composed of Gα, Gβ, and Gγ subunits. While Gβ and Gγ are associated to a dimer, the membrane-associated trimer is only present in the inactivated state when Gα is in its GDP-bound inactive state. Upon ligand binding to a G-protein coupled receptor, the exchange of GDP to GTP in Gα is induced, leading to dissociation of the activated Gα from the Gβγ dimer and the subsequent activation of effectors and downstream signaling pathways. This leads to varying cellular effects depending on the individual G-protein subtype which is determined by
the particular \( \alpha \) subunit \([5]\). Specific substrates of PMTs enzymatic activity are the subtypes \( \text{G}_\alpha q/11 \), \( \text{G}_\alpha i1,2,3 \), and \( \text{G}_\alpha 12/13 \), leading to the deamidation of a target glutamine, thereby prohibiting the intrinsic GTPase activity of \( \text{G}_\alpha \), which inhibits the transition of the bound GTP to GDP keeping the G-protein in a permanently active state \([6–8]\). This results in strong mitogenic and anti-apoptotic effects and modulates cell differentiation \([7,9–11]\). Structurally, PMT is a 146 kDa protein containing 1285 amino acids \([12]\). It is composed of an N-terminal part that is necessary for toxin uptake and translocation and a C-terminal part which is required for enzymatic activity \([13,14]\). The C-terminal part can be subdivided into three distinct domains: C1, C2, and C3. Domain C3 possesses deamidase activity. C3 also contains a structurally important disulfide bond that needs to be reduced to achieve full enzymatic activity \([15]\). Like other bacterial AB-type toxins, PMT exploits the endocytic mechanisms of host cells for its cellular uptake. While the receptor for PMT binding is still elusive, the internalization of the toxin is assumed to be accomplished by receptor-mediated endocytosis, followed by endosomal trafficking and acidification, leading to the release of the enzymatically active domain of PMT from acidified endosomes into the cytosol \([16,17]\).

In the present study, we investigated the molecular mechanisms underlying the transport of the enzyme domain of PMT across cell membranes. Cultured human cells were protected from intoxication with PMT in the presence of auranofin. Auranofin—a small molecule gold compound which was originally used as a treatment for rheumatoid arthritis—has been shown to be an effective and specific inhibitor of thioredoxin reductase (TrxR) \([18]\). Treatment of cells with this compound leads to an alteration of the reductive potential of the cytosol, which efficiently protected cells from intoxication with other bacterial toxins that also contain structurally important disulfide bonds such as Clostridium (C.) botulinum neurotoxin (BoNT) and diphtheria toxin (DT) \([19,20]\).

2. Results

Since most cell types show no obvious morphological changes after treatment with PMT, the intoxication of cells is determined by analyzing the specific PMT-catalyzed deamidation of \( \text{G}_\alpha q \) subunits in the host cell cytosol by Western blotting with a specific antibody against the deamidated form of \( \text{G}_\alpha q \) \([8,15]\). In this assay, deamidated \( \text{G}_\alpha q \) serves as a marker protein for the PMT-catalyzed modification of \( \text{G}_\alpha \) proteins in cells, but this antibody also detects several other deamidated \( \text{G}_\alpha \) subtypes \([8,15]\). This approach allows the specific and sensitive detection of the enzyme activity of PMT in cells, because no signal is detected in untreated cells (not shown) or in cells treated with PMT in the presence of bafilomycin A1 (BafA1) (Figure 1A). This well-established inhibitor prevents endosomal acidification, by inhibition of vacuolar-type \( H^+ \) –ATPases, and inhibits the translocation of the enzyme domain of PMT into the cytosol, as shown previously \([16,17,21]\).

By using this approach, we first demonstrated that preincubation of HeLa cells with auranofin reduced the PMT-catalyzed deamidation of \( \text{G}_\alpha q \) in PMT-treated cells (Figure 1A). In cells treated with PMT alone, there was a higher amount of deamidated \( \text{G}_\alpha q \), while in cells treated with PMT in the presence of BafA1, no deamidated \( \text{G}_\alpha q \) was detected, indicating that the enzyme domain of PMT did not reach the cytosol. The inhibitory effect of auranofin was also shown by treatment of cells with increasing concentrations of PMT in the absence or presence of auranofin (Figure 1B). The results clearly indicate that less \( \text{G}_\alpha q \) was deamidated in PMT-treated cells in the presence of auranofin, meaning that less active PMT was in the cytosol, suggesting that the TrxR activity of cells is crucial for the mode of action of PMT. However, from this observation, it could not be concluded whether the enzyme activity of PMT was inhibited in auranofin-treated cells or whether less of the enzyme domain of PMT reached the cytosol in cells treated with PMT in the presence of auranofin.

To address this question, we exploited a PMT mutant without the disulfide to investigate the molecular mechanisms underlying the inhibition of PMT intoxication by auranofin in more detail. In wild-type PMT, the peripheral cysteine residue at position 1159 is in close proximity to another cysteine residue at position 1165 in the C3-deamidase domain of PMT, which is assumed to play a major role in the enzymatic activity of PMT. Both cysteine residues form a disulfide bond that needs to be
reduced to enable full enzymatic activity [7], but the reducing system in cells that catalyzes this cleavage is not known. By exchange of the peripheral cysteine residue 1159 to a serine residue, no disulfide bond is formed, and PMTC1159S is enzymatically active—even under non-reducing conditions [15]. Therefore, PMTC1159S was tested in direct comparison to wild-type PMT regarding the inhibitory effect of auranofin in a cell intoxication experiment. In the Western blot analysis shown in Figure 1C, there are comparable amounts of deamidated Gαq from cells treated with PMTC1159S independent of whether or not cells were pretreated with auranofin. In contrast, pretreatment of cells with auranofin clearly reduced the amount of deamidated Gαq in cells treated with wild-type PMT (Figure 1C). Taken together, this result clearly indicates that the disulfide bond in the enzyme domain of PMT is crucial for the inhibitory effect of auranofin towards the intoxication of cells with PMT. The finding that intoxication of cells by PMTC1159S was not reduced by auranofin indicates that the transport of PMTC1159S into the host cell cytosol was independent of TrxR activity. This suggests that TrxR of host cells might not be crucial for the translocation of PMT from endosomal vesicles into the cytosol, but is involved in the reduction of the disulfide bond in PMT to activate its enzyme domain in the cytosol of living cells.

**Figure 1.** Effect of auranofin on *Pasteurella multocida* toxin (PMT) intoxication of HeLa cells analyzed by Western blotting of deamidated Gαq from PMT-treated cells. (A) Preincubation with auranofin reduces the deamidation of Gαq after treatment of cells with PMT. Cells were pretreated for 30 min at 37 °C in serum-free medium with 1 µM auranofin, 100 nM BafA1, or were left untreated. Then, PMT (5 nM) was added, and cells were further incubated for 3 h. Subsequently, cells were lysed and analyzed by Western blotting with a specific antibody for deamidated Gαq. Comparable protein loading was confirmed by detecting HSP90 from the lysates. The bar graph shows quantified levels of Gαq (normalized to HSP90 loading control and treatment control set as 100%); (B) Effect of increasing PMT concentrations on substrate modification levels with or without inhibitor treatment. Bar graph shows quantified levels of Gαq (normalized to HSP90 loading control and treatment control set as 100%); (C) Effect of auranofin on the intoxication of cells with either wild-type PMT (5 nM) or the mutated activated PMTC1159S (5 nM). Bar graph shows quantified levels of Gαq (normalized to HSP90 loading control and treatment control set as 100%). Significance was tested by using the Student’s t-test.

*p < 0.05, **p < 0.01, n.s. = non-significant (n = 3).
So far, the results suggest that the inhibitory effect of auranofin is dependent on the inhibition of TrxR, which in turn prevents the reduction of the disulfide bond in the catalytic domain of PMT. To exclude the possibility that auranofin has a direct effect on the enzymatic activity of PMT, a cell-free enzyme activity assay was performed.

To this end, we analyzed the in vitro enzyme activity of the catalytic C3-domain of three different PMT proteins: wild-type PMT, PMT<sub>C1165S</sub> (which is enzymatically inactive), and PMT<sub>C1159S</sub>, which exhibits full enzyme activity independent of any reducing activities due to the loss of the disulfide bond, as described before. Each of these proteins was incubated with chimeric G<sub>αq</sub> protein—a recombinantly expressable variant of G<sub>αq</sub>—in the absence and presence of auranofin, and the amount of deamidated G<sub>αq</sub> was analyzed by Western blotting (Figure 2).

![Western blot analysis to detect the enzyme activity of the catalytic domains of wild-type and mutated PMT in a cell-free system. (A) Recombinant G<sub>αq</sub> was incubated at 16 °C for 20 h with the recombinant C3-deamidase domains of either wild-type (WT) PMT, enzymatically inactive PMT<sub>C1165S</sub>, or PMT<sub>C1159S</sub> in the presence or absence of 1 μM auranofin. Western blotting was performed to visualize the amounts of deamidated and total G<sub>αq</sub>; (B) Bar graph shows quantified levels of deamidated G<sub>αq</sub> (normalized to total G<sub>αq</sub> loading control and C1159S control set as 100%). Significance was tested by using the Student’s t-test. n.s. = non-significant (n = 3).](image)

While incubation with the inactive catalytic domain of PMT<sub>C1165S</sub> did not result in substrate modification, the catalytic domain of wild-type PMT showed some residual enzyme activity, and a strong deamidation was detected in the samples incubated with the catalytic domain of PMT<sub>C1159S</sub>, which does not require disulfide reduction to exhibit its enzyme activity. In each case, however, the presence of auranofin had no obvious effect on the enzyme activity. The result that auranofin did not reduce the enzyme activity of PMT<sub>C1159S</sub> clearly indicates that this inhibitor did not act directly on the catalytic domain of PMT, but most likely by inhibiting the TrxR in cells.

Taken together, our findings provide strong evidence that during cellular uptake of PMT, the TrxR plays a crucial role in the activation of the catalytic domain of PMT in the host cell cytosol.

3. Discussion and Conclusions

Bacterial protein AB-type toxins show a variety of host cell dependencies, and very efficiently exploit cellular mechanisms with a completely different physiological intention, such as receptor-mediated endocytosis for their internalization into cells and protein folding machineries of host cells for the subsequent translocation of their enzymatically active subunits into the cytosol [22,23]. In recent years, a novel host cell dependency came into focus in the context of the cellular uptake of bacterial toxins that contain structurally-relevant disulfide bonds. For the clostridial tetanus and botulinum neurotoxins, Pirazzini and colleagues reported that the reductive conditions of the cytosol are necessary for their full activity [19]. Similarly, in previous work from our group, it was demonstrated that the intracellular membrane transport of the enzyme subunit of diphtheria toxin is effectively inhibited by driving cellular conditions to a more oxidative state [20]. Both studies used auranofin as a specific inhibitor of TrxR in living cells, thereby reducing the potential of the cytosolic disulfide bond reduction. Additionally, all tested toxins have a structurally important disulfide bond connecting their enzymatically active
domain which needs to be translocated into the cytosol, with their corresponding delivery domain. Therefore, cytosolic reduction of this bond is a requirement for the toxin to be fully functional.

Here, we show that this necessity is not limited to such inter-domain disulfide bonds, but is also important for the activation of the intra-domain disulfide within the enzymatic domain of PMT. The dependency of reductive conditions for the full activity of wild-type PMT has already been demonstrated before [15], but the relevance for intoxication in a cell-based assay was not given. First trials with auranofin as an inhibitor revealed that there is a defined decrease in amount of modified substrate when cells were pretreated with the compound prior to the application of PMT. Compared to treatment with BaF1, there was no complete inhibition of the enzymatic effect, but an obvious reduction. This could be explained by the presence of alternative reduction pathways [24] and empirically determined dose limitations of auranofin that consider toxic effects on cells. PMT intoxication with increasing amounts of toxin led to increased substrate deamidation in the cells, which could also be inhibited by pretreatment of the cells with auranofin. This indicates that the inhibitory effect cannot just be circumvented by increasing the amount of enzymatically active agent, but is directly dependent on the reductive potential of the cytosol, and thereby on the amount of activated PMT. Additional evidence that auranofin indirectly inhibits activation of PMT via pharmacological modulation of a cellular activation process was given by using PMT<sub>C1159S</sub>, which has no disulfide bond formed, and is therefore in a constitutively active state. While wild-type PMT activity was decreased in the presence of auranofin, no such effect was detected in the PMT<sub>C1159S</sub> samples, showing that this mutant does not need the reductive potential of the cytosol.

To exclude that the auranofin effect towards PMT-induced cell intoxication is caused by a direct action on the enzymatically active C3-domain of PMT, we analyzed the enzyme activity of different PMT variants with recombinant G<sub>oxt</sub> in vitro. Under these conditions (without a reducing system, e.g., TrxR), the activity of wild-type PMT was not influenced by auranofin. As expected, the inactive mutant PMT<sub>C1165S</sub> was without activity, and PMT<sub>C1159S</sub> exhibited the highest activity because it cannot form an inactive disulfide bond. The finding that auranofin did not alter the activity of any of the PMT variants supports the view that the inhibitor does not directly interact with the enzymatic domain of the toxin.

Taken together, the results provide evidence that TrxR of host cells is crucial for the activation of the enzyme domain of PMT in the cytosol of mammalian cells, and this process is inhibited by the compound auranofin, a specific pharmacological inhibitor of TrxR in cells (Figure 3).

**Figure 3.** Schematic representation of PMT and the cellular mode of action of auranofin. In the native state, endogenous reduced thioredoxin reductase (TrxR) reduces thioredoxin (Trx), which leads to the reduction of various substrate molecules within the cell. Thereby, also reducing the disulfide bond of the C3-domain of PMT, which leads to its activation. Auranofin binds to the selenocysteine of reduced TrxR, which blocks the downstream reduction of substrate molecules, keeping PMT in its inactive state. Our results suggest that PMT is used as a substrate of the TrxR system, and needs the reducing environment of the cytosol for its cytotoxicity.
Moreover, the findings demonstrate that auranofin can serve as an effective pharmacological inhibitor to protect human cells from an intoxication with PMT. This demonstrates that auranofin not only acts against bacterial protein toxins with structurally important inter-domain disulfide bonds [19,20], but also against a toxin that harbors a disulfide bond within its enzymatically active domain. The results not only contribute to a better understanding of the cellular uptake of PMT, but might be a starting point for the development of novel therapeutic strategies against PMT-associated diseases.

In conclusion, the exploitation of the reductive cytosolic conditions of mammalian target cells for toxin activation is likely a feature which is shared between various bacterial toxins that are not closely related to each other. Therefore, auranofin—a licensed drug for treatment of other human diseases—might serve for prevention and/or treatment of diseases which are associated with certain bacterial toxins.

4. Materials and Methods

4.1. Materials

Chemicals and salts were obtained from Carl Roth (Karlsruhe, Germany) and AppliChem (Darmstadt, Germany). Cell culture media and supplements were obtained from Gibco (Karlsruhe, Germany). Primary α-HSP90 antibody (mouse) and secondary goat-α-mouse-horseradish peroxidase (HRP) antibody were obtained from SantaCruz Biotechnology (Heidelberg, Germany). Secondary goat-α-rat-HRP antibody was obtained Cell Signaling (Danvers, MA, USA). Deamidated Gαq specific antibody (rat) was kindly provided by Dr. Y. Horiguchi (Osaka University, Japan).

4.2. Cell Culture

HeLa cells were cultivated in Minimum Essential Medium (MEM) supplemented with 10% fetal calf serum (FCS), 1% sodium pyruvate (100 mM), 1% non-essential amino acid solution (NEAA), 1% glutamine (200 mM), and 1% penicillin/streptomycin solution. Standard incubation was at 37 °C in a 5% CO₂ atmosphere with constant humidity until cells reached near confluency on the dish. Cells were trypsinized and diluted twice a week for continuous cell culture.

4.3. PMT and PMT Mutants

PMT, PMT fragments, and PMT mutants were cloned into pCOLDII expression vector system by standard cloning techniques and expressed as N-terminal His₆ fusion constructs [6].

4.4. PMT Cell Intoxication Assay and Western Blot Detection of Deamidated Gαq

For the PMT intoxication assay, 8 × 10⁵ HeLa cells were seeded in a 12-well plate 48 h prior to the assay in 1 mL of serum containing MEM. Cells were then treated with PMT<sub>WT</sub> or PMT<sub>C1159S</sub> (concentrations indicated in results) in 1 mL serum-free MEM for 3 h at 37 °C, 5% CO₂, and constant humidity. Intracellular acting inhibitors (BafA1 and auranofin) were preincubated in 1 mL serum free MEM 30 min prior to the intoxication in corresponding samples, and were also present during the whole incubation time. After intoxication, incubation medium was discarded, and cells were washed twice with PBS-buffer (137 mM NaCl, 2.7 mM KCl, 8 mM Na₂HPO₄, 1.8 mM KH₂PO₄, pH 7.4). Successively, cells were lysed with 40 µL of hot (95 °C) 2.5-fold Laemmli sample-buffer (150 mM Tris-Cl pH 6.8, 5% SDS (w/v), 18.75% glycerol, 0.25 mg/mL bromophenol blue) per well. Entire lysate mixtures were then applied to protein gels and subjected to SDS-PAGE with subsequent Western blotting on 0.45 µm nitrocellulose membranes. Unspecific binding sites were then blocked with 5% skimmed milk powder (w/v) diluted in PBS-T—PBS supplemented with 0.1% Tween 20 (v/v) for 1 h at room temperature on a rocking shaker with 25 rpm. Membranes were then split into two parts at the 70 kDa ladder band. The upper part was treated with α-HSP90 antibody (mouse, 1:1000 diluted in PBS-T), and the lower part with α-deamidated Gαq antibody (rat, 1:250 diluted in PBS-T). Both membranes
were incubated overnight at 4 °C on a rocking shaker (50 rpm). Afterwards, they were treated with corresponding secondary antibodies (either goat-α-mouse-HRP or goat-α-rat-HRP; 1:2500 diluted in PBS-T) for 1 h at room temperature on a rocking shaker. HRP was then visualized using luminescence substrate and X-ray films.

4.5. In Vitro Enzyme Activity of PMT

To test for in vitro activity of PMT and its mutants, samples with 20 µL of assay buffer containing recombinant Gαq-α-subunits (1 µM) were incubated with PMT-C3 deamidase domains (10 nM) of either wild-type PMT, the activated mutant (PMTC1159S), or the inactivated mutant (PMTC1165S) in the presence of either auranofin (1 µM) or its solvent DMSO (0.02%, control) for 20 h at 16 °C. Samples were then supplemented with 5-fold Laemmli sample buffer and subjected to SDS-PAGE with subsequent Western blotting. For detection of deamidated Gαq, membranes were treated as described above. As loading control, Gαq was detected with Gαq/11 (C-19) antibody (rabbit, 1:2000 diluted in TBS-T/5% BSA (bovine serum albumin)) and goat-α-rabbit antibody (1:2500 diluted in TBS-T) as secondary antibody.

4.6. Reproducibility of the Experiments

Experiments were performed independently at least three times and results from representative experiments are shown in the figures.

Acknowledgments: Katharina Ernst is thanked for critical reading of the manuscript. We thank Yasuhiko Horiguchi (Osaka University, Japan) for deamidation specific antibody. This work was financially supported by the International Graduate School in Molecular Medicine Ulm (iGradU). Stefan Carle is a member of iGradU and funded by a research scholarship of the graduate school.

Author Contributions: Conceived and designed the experiments: H.B., J.H.C.O.; Performed the experiments: S.C., T.B.; Analyzed the data: H.B., S.C.; Wrote the paper: H.B., S.C.; Contributed essential materials, reagents, tools: K.A., J.H.C.O.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Wilkie, I.W.; Harper, M.; Boyce, J.D.; Adler, B. Pasteurella multocida: Diseases and pathogenesis. Curr. Top. Microbiol. Immunol. 2012, 361, 1–22. [PubMed]
2. Orth, J.H.C.; Aktories, K. Molecular biology of Pasteurella multocida toxin. Curr. Top. Microbiol. Immunol. 2012, 361, 73–92. [PubMed]
3. Wilson, B.A.; Ho, M. Pasteurella multocida: From Zoonosis to cellular microbiology. Clin. Microbiol. Rev. 2013, 26, 631–655. [CrossRef] [PubMed]
4. Pedersen, K.B.; Elling, F. The pathogenesis of atrophic rhinitis in pigs induced by toxigenic Pasteurella multocida. J. Comp. Pathol. 1984, 94, 203–214. [CrossRef]
5. Hamm, H.E.; Gilchrist, A. Heterotrimeric G proteins. Curr. Opin. Cell Biol. 1996, 8, 189–196. [CrossRef]
6. Orth, J.H.C.; Preuss, I.; Fester, I.; Schlosser, A.; Wilson, B.A.; Aktories, K. Pasteurella multocida toxin activation of heterotrimeric G proteins by deamidation. Proc. Natl. Acad. Sci. USA 2009, 106, 7179–7184. [CrossRef] [PubMed]
7. Orth, J.H.C.; Aktories, K. Pasteurella multocida toxin activates various heterotrimeric G proteins by deamidation. Toxins (Basel) 2010, 2, 205–214. [CrossRef] [PubMed]
8. Orth, J.H.C.; Fester, I.; Siegert, P.; Weise, M.; Lanner, U.; Kamitani, S.; Tachibana, T.; Wilson, B.A.; Schlosser, A.; Horiguchi, Y.; et al. Substrate specificity of Pasteurella multocida toxin for α subunits of heterotrimeric G proteins. FASEB J. 2013, 27, 832–842. [CrossRef] [PubMed]
9. Rozengurt, E.; Higgins, T.; Chanter, N.; Lax, A.J.; Staddon, J.M. Pasteurella multocida toxin: Potent mitogen for cultured fibroblasts. Proc. Natl. Acad. Sci. USA 1990, 87, 123–127. [CrossRef] [PubMed]
10. Preuß, I.; Hildebrand, D.; Orth, J.H.C.; Aktories, K.; Kubatzky, K.F. Pasteurella multocida toxin is a potent activator of anti-apoptotic signalling pathways. Cell. Microbiol. 2010, 12, 1174–1185. [CrossRef] [PubMed]
11. Gwaltney, S.M.; Galvin, R.J.; Register, K.B.; Rimler, R.B.; Ackermann, M.R. Effects of Pasteurella multocida toxin on porcine bone marrow cell differentiation into osteoclasts and osteoblasts. *Vet. Pathol.* 1997, 34, 421–430. [CrossRef] [PubMed]

12. Petersen, S.K. The complete nucleotide sequence of the Pasteurella multocida toxin gene and evidence for a transcriptional repressor, TxaR. *Mol. Microbiol.* 1990, 4, 821–830. [CrossRef] [PubMed]

13. Busch, C.; Orth, J.; Djouder, N.; Aktories, K. Biological Activity of a C-Terminal Fragment of Pasteurella multocida Toxin. *Infect. Immun.* 2001, 69, 3628–3634. [CrossRef] [PubMed]

14. Kitadokoro, K.; Kamitani, S.; Miyazawa, M.; Hanajima-Ozawa, M.; Fukui, A.; Miyake, M.; Horiguchi, Y. Crystal structures reveal a thiol protease-like catalytic triad in the C-terminal region of Pasteurella multocida toxin. *Proc. Natl. Acad. Sci. USA* 2007, 104, 5139–5144. [CrossRef] [PubMed]

15. Kamitani, S.; Ao, S.; Toshima, H.; Tachibana, T.; Hashimoto, M.; Kitadokoro, K.; Fukui-Miyazaki, A.; Abe, H.; Horiguchi, Y. Enzymatic actions of Pasteurella multocida toxin detected by monoclonal antibodies recognizing the deamidated α-subunit of the heterotrimeric GTPase Gq. *FEBS J.* 2011, 278, 2702–2712. [CrossRef] [PubMed]

16. Baldwin, M.R.; Lakey, J.H.; Lax, A.J. Identification and characterization of the Pasteurella multocida toxin translocation domain. *Mol. Microbiol.* 2004, 54, 239–250. [CrossRef] [PubMed]

17. Bergmann, S.; Jehle, D.; Schwan, C.; Orth, J.H.C.; Aktories, K. Pasteurella multocida toxin as a transporter of non-cell-permeating proteins. *Infect. Immun.* 2013, 81, 2459–2467. [CrossRef] [PubMed]

18. Marzano, C.; Gandin, V.; Folda, A.; Scutari, G.; Bindoli, A.; Rigobello, M. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. *Free Radic. Biol. Med.* 2007, 42, 872–881. [CrossRef] [PubMed]

19. Pirazzini, M.; Bordin, F.; Rossetto, O.; Shone, C.C.; Binz, T.; Montecucco, C. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. *FEBS Lett.* 2013, 587, 150–155. [CrossRef] [PubMed]

20. Schnell, L.; Dmochewitz-Kück, L.; Feigl, P.; Montecucco, C.; Barth, H. Thioredoxin reductase inhibitor auranofin prevents membrane transport of diphtheria toxin into the cytosol and protects human cells from intoxication. *Toxicon* 2015, 116, 23–28. [CrossRef] [PubMed]

21. Yoshimori, T.; Yamamoto, A.; Moriyama, Y.; Futai, M.; Tashiro, Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. *J. Biol. Chem.* 1991, 266, 17707–17712. [PubMed]

22. Lord, J.M.; Smith, D.C.; Roberts, L.M. Toxin entry: How bacterial proteins get into mammalian cells. *Cell. Microbiol.* 1999, 1, 85–91. [CrossRef] [PubMed]

23. Barth, H.; Ernst, K. Chaperones and ADP-Ribosylating Bacterial Toxins. In *Microbial Toxins*; Springer: Dordrecht, The Netherlands, 2016; pp. 1–22.

24. Holmgren, A. Thioredoxin and glutaredoxin systems. *J. Biol. Chem.* 1989, 264, 13963–13966. [PubMed]

© 2017 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).